TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30611215

Group type: EXPERIMENTAL
Intervention: Neutral position
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sniffing position
Number of subjects: 54
Study: 28157491

Group type: EXPERIMENTAL
Intervention: 16 mg dexamethasone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0 mg dexamethasone (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 16 mg and 8 mg dexamethasone
Number of subjects: 24
Study: 26439756

Group type: EXPERIMENTAL
Intervention: Early intervention program with regular home visits commencing antenatally and a parenting course starting at 2 years
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Early intervention program
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 233
Study: 23332349

Group type: EXPERIMENTAL
Intervention: Docetaxel followed by capecitabine (D → C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Docetaxel administered concomitantly with capecitabine (DC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients with triple-negative breast cancer
Number of subjects: 51
Study: 21085036

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 16 weeks
Number of subjects: 319

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 319
Study: 19471901

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions and coping skills training (QE)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional detoxification treatment (KE)
Number of subjects: 117
Study: 16881464

Group type: EXPERIMENTAL
Intervention: Specific-exercise-training group (Pilates-based therapeutic exercise)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 39
Study: 15005830

Group type: EXPERIMENTAL
Intervention: Prandial subcutaneous injections of rGLP-1 (76 nmol 30 min before meals, four times daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prandial subcutaneous injections of rGLP-1
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of rGLP-1 (12.7 nmol/h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11352777

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia and caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hypoglycaemia and placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Euglycaemia and caffeine
Number of subjects: 16
Study: 9509071

Group type: EXPERIMENTAL
Intervention: Bright light exposure from 2000 h to 0200 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal room lighting from 2000 h to 0200 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal room lighting from 2000 h to 2400 h
Number of subjects: 10
Study: 7522527

Group type: EXPERIMENTAL
Intervention: CABO (cisplatin, methotrexate, bleomycin, and vincristine)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: CF (cisplatin and 5-fluorouracil)
Number of subjects: 382

Group type: COMPARATOR
Intervention: C (cisplatin)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: CABO
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: CF
Number of subjects: 382

Group type: COMPARATOR
Intervention: C
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: CABO and CF
Number of subjects: 382

Group type: COMPARATOR
Intervention: CABO, CF, and C
Number of subjects: 382
Study: 3257915

Group type: EXPERIMENTAL
Intervention: Atenolol (started 72 h before operation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no atenolol)
Number of subjects: 60
Study: 30418256

Group type: EXPERIMENTAL
Intervention: WeChat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 0
Study: 29684501

Group type: EXPERIMENTAL
Intervention: Sputum rheology measures (G', G" and solids content)
Number of subjects: 15
Study: 26654252

Group type: EXPERIMENTAL
Intervention: Foot Exercise Group (FEG - extrinsic and intrinsic foot muscles)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Foot and Hip Exercise Group (FHEG - abductor and lateral rotator muscles)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Stretching Alone Exercise Group (SAEG)
Number of subjects: 83

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 83
Study: 25285767

Group type: EXPERIMENTAL
Intervention: Blanketrol II (Automatic control mode)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blanketrol III (Gradient mode)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 0
Study: 22832329

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion (two concentrations)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion (highest dose level)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20819318

Group type: EXPERIMENTAL
Intervention: Levocetirizine 1.25 mg (q.d. for infants, b.i.d. for children)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 17934678

Group type: EXPERIMENTAL
Intervention: Interactive seminar training for practice nurses
Number of subjects: 629

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Routine asthma outcome measures (beta2-agonist prescription rate and number of oral steroid courses)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Questionnaire data (Mini AQLQ and Asthma Control Questionnaire)
Number of subjects: 629
Study: 15743537

Group type: EXPERIMENTAL
Intervention: Soy extract capsules (2 capsules containing daidzin : genistin = 7.79 : 22.57 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soy beverage (prepared from 15 g of soy flour containing daidzin : genistin = 9.27 : 10.51 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soy extract capsules
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soy beverage
Number of subjects: 12
Study: 10682229

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Quality-of-life outcomes
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Economic outcomes
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Functional imaging outcomes
Number of subjects: 301
Study: 9052446

Group type: EXPERIMENTAL
Intervention: Standard diet supplemented with 30 g per day of L-arginine for 3 days before surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard hospital diet (controls)
Number of subjects: 18
Study: 7511242

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Maternal serum alpha-fetoprotein (AFP) measurement
Number of subjects: 76
Study: 2868480

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: procyclidine
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 2893865

Group type: EXPERIMENTAL
Intervention: Intravenous penicillin (6 million units/day for 7 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31749238

Group type: EXPERIMENTAL
Intervention: Bexagliflozin 5 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Bexagliflozin 10 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Bexagliflozin 20 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Bexagliflozin (all doses)
Number of subjects: 292
Study: 31381171

Group type: EXPERIMENTAL
Intervention: High dose of alcohol (mean BrAC = 0.11%)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (mean BrAC = 0.04%)
Number of subjects: 98
Study: 28969667

Group type: EXPERIMENTAL
Intervention: CRP point-of-care test (POCT) to guide antibiotic prescribing
Number of subjects: 650

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: CRP POCT
Number of subjects: 650
Study: 24794584

Group type: EXPERIMENTAL
Intervention: TTM-tailored intervention
Number of subjects: 828

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 828
Study: 24231273

Group type: EXPERIMENTAL
Intervention: Interspinous process device
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard bony decompression
Number of subjects: 159
Study: 22204615

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2 mA, 20 mins)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (20 mins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation followed by cognitive-behavioral group programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation followed by cognitive-behavioral group programme
Number of subjects: 0
Study: 19481728

Group type: EXPERIMENTAL
Intervention: Mental imagery sessions
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reading a book chapter describing cystoscopy (Control)
Number of subjects: 68
Study: 16982287

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 79
Study: 14982685

Group type: EXPERIMENTAL
Intervention: bupropion (300 mg) with behavioral counseling for 10 weeks
Number of subjects: 555

Group type: COMPARATOR
Intervention: placebo with behavioral counseling
Number of subjects: 555
Study: 11387607

Group type: EXPERIMENTAL
Intervention: Large burrs (burr/artery ratio of >0.7)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Small burrs (burr/artery ratio < or = 0.7)
Number of subjects: 222
Study: 9000704

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 1008
Study: 7683552

Group type: EXPERIMENTAL
Intervention: rhuG-CSF 20 micrograms/kg/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: rhuG-CSF
Number of subjects: 121
Study: 3325289

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31065120

Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Misoprostol Alone
Number of subjects: 60
Study: 28872196

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 183
Study: 26302441

Group type: EXPERIMENTAL
Intervention: LAI risperidone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Oral risperidone
Number of subjects: 95
Study: 23792133

Group type: EXPERIMENTAL
Intervention: Behaviorally-centered, culturally-tailored lifestyle intervention delivered by trained AA community health workers (CHW) during 16 contacts
Number of subjects: 200

Group type: COMPARATOR
Intervention: Approved diabetes educational mailings (control group)
Number of subjects: 200
Study: 21431408

Group type: EXPERIMENTAL
Intervention: CRS + HIPEC (cisplatin 120 mg and mitomycin C 30 mg in 6000 ml of normal saline at 43 ± 0.5°C for 60-90 min)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CRS alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CRS + HIPEC
Number of subjects: 68
Study: 18305083

Group type: EXPERIMENTAL
Intervention: NaCl 7.5% (HS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: NaCl 0.9% 32 ml kg(‐1) (NS32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: NaCl 0.9% (NS4)
Number of subjects: 62
Study: 17140532

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Carisolv(TM)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Rotary instruments
Number of subjects: 217

Group type: COMPARATOR
Intervention: Operator effect
Number of subjects: 217
Study: 12572334

Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical tracheostomy
Number of subjects: 0
Study: 10606834

Group type: EXPERIMENTAL
Intervention: 10 mg fosinopril (n=12 patients)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 2.5 mg enalapril (n=12 patients)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 10 mg fosinopril (n=16 patients)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 5 mg lisinopril (n=15 patients)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fosinoprilat
Number of subjects: 55
Study: 9105340

Group type: EXPERIMENTAL
Intervention: Computerized balance training
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 72

Group type: COMPARATOR
Intervention: Educational group (Control)
Number of subjects: 72
Study: 8240458

Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg/day for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16
Study: 3513558

Group type: EXPERIMENTAL
Intervention: 0.22 micron filterset (real filter)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Filter cartridge without a 0.22 micron membrane (blank filter)
Number of subjects: 70
Study: 31933301

Group type: EXPERIMENTAL
Intervention: Participation in the quit smoking project
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Receiving invitation to join the program
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Participants' willingness to participate in the program
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Knowledge and communication skills
Number of subjects: 626
Study: 29390128

Group type: EXPERIMENTAL
Intervention: Standard models to analyze cluster‐randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlling for amount of time exposed to the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analyzing subsets of workers with least mobility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reanalysis of previously conducted trial
Number of subjects: 0
Study: 26961765

Group type: EXPERIMENTAL
Intervention: Insufficient sleep (<10 hrs/day)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Sufficient sleep (≥10 hrs/day)
Number of subjects: 298
Study: 25282563

Group type: EXPERIMENTAL
Intervention: Daily emollient therapy applied at least once per day starting within 3 weeks of birth
Number of subjects: 124
Study: 23144893

Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 21073605

Group type: EXPERIMENTAL
Intervention: OAB-M-F (metronidazole 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Number of subjects: 310

Group type: COMPARATOR
Intervention: OAC-P (clarithromycin 500 mg bid for 10 days, placebo)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: OAB-C-F (clarithromycin 500 mg bid for 5 days, followed by furazolidone 200 mg bid for 5 days)
Number of subjects: 310
Study: 17713873

Group type: EXPERIMENTAL
Intervention: 2% sage extract (SE) in a hydrophilic ointment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 40
Study: 15854934

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 818

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 818
Study: 12153334

Group type: EXPERIMENTAL
Intervention: Nefazodone (starting at 50 mg/day, increasing to 200 mg/day, and up to 600 mg/day if tolerated)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 79
Study: 9832659

Group type: EXPERIMENTAL
Intervention: 1% diphenhydramine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% buffered lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% benzyl alcohol with epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All anesthetics
Number of subjects: 30
Study: 7977066

Group type: EXPERIMENTAL
Intervention: High serum lipoprotein(a) levels
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: High serum homocyst(e)ine levels
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Patients with > or = 1 occluded vein graft
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Lowest quartile of lipoprotein(a) levels
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Preoperative serum lipoprotein(a) and homocyst(e)ine levels
Number of subjects: 610
Study: 2521552

Group type: EXPERIMENTAL
Intervention: Inhaled pirenzepine (70 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (7 micrograms)
Number of subjects: 0
Study: 30457934

Group type: EXPERIMENTAL
Intervention: Early contact condition (2-week follow-up contact)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control condition (no early follow-up)
Number of subjects: 800
Study: 28505360

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefazolin (500 mg h-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent bolus of cefazolin (2 g every 4 h)
Number of subjects: 20
Study: 26931670

Group type: EXPERIMENTAL
Intervention: Above-median consumption of milk
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Above-median consumption of fruits and vegetables
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Moderate consumption of yogurts and cottage cheese
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Above-median consumption of other cheeses
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Above-median consumption of bread
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Highest sodium intakes
Number of subjects: 960
Study: 25005464

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gram orally 3 times daily for 3 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (1 gram orally 3 times daily for 3 months)
Number of subjects: 22
Study: 21334223

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 6 months
Number of subjects: 36
Study: 20477776

Group type: EXPERIMENTAL
Intervention: Combined parent-based intervention (PBI) and brief motivational intervention (BMI)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Parent-based intervention (PBI)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 1275
Study: 16983692

Group type: EXPERIMENTAL
Intervention: Molecular water (via vaporizing humidifier)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Particulate water (via aerosol spray)
Number of subjects: 10
Study: 16357661

Group type: EXPERIMENTAL
Intervention: Developmental physical therapy (PT) from birth until four months corrected age (CA), weekdays during the neonatal stay and on a needs- and problem-oriented basis thereafter.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nontreatment (NT) group (no intervention).
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group of infants born full term (n = 14).
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Developmental PT with high levels of parental compliance.
Number of subjects: 72
Study: 12409172

Group type: EXPERIMENTAL
Intervention: haloperidol or quetiapine
Number of subjects: 10

Group type: COMPARATOR
Intervention: normal controls
Number of subjects: 10
Study: 10776294

Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no visual stimulation)
Number of subjects: 2
Study: 10500946

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg kg‐1 (Group M)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms kg‐1 (Group F)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 180
Study: 1907447

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 0
Study: 6859607

Group type: EXPERIMENTAL
Intervention: Thiopental 3 mg/kg, iv, followed by inhalation of 100% oxygen and a continuous intravenous infusion of thiopental 0.2‐0.3 mg X kg‐1 X min‐1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiopental 3 mg/kg followed by inhalation of halothane (1.5% end‐tidal concentration) in oxygen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiopental 3 mg/kg followed by inhalation of 70% nitrous oxide in oxygen
Number of subjects: 24
Study: 31911613

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 9237

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 9237
Study: 31409425

Group type: EXPERIMENTAL
Intervention: Stop-X intervention (home-based motor-control training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative guideline rehabilitation plus Classic follow-up treatment
Number of subjects: 0
Study: 26944808

Group type: EXPERIMENTAL
Intervention: Get Active
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sit Less
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 38
Study: 26725296

Group type: EXPERIMENTAL
Intervention: Supported-employment services (randomization)
Number of subjects: 194
Study: 27142743

Group type: EXPERIMENTAL
Intervention: Theaflavins (TF) 10mg/kg single oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theaflavins (TF) 10mg/kg/day for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theaflavin drink (45mg/drink)
Number of subjects: 0
Study: 23828232

Group type: EXPERIMENTAL
Intervention: Violent offenders
Number of subjects: 29
Study: 22315746

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) nasal spray 110 microg/day
Number of subjects: 220

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) nasal spray 200 microg/day
Number of subjects: 220
Study: 17928806

Group type: EXPERIMENTAL
Intervention: 1000 mg elemental calcium daily for 30 days (n=24)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Calcium group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 44
Study: 16905024

Group type: EXPERIMENTAL
Intervention: Insecticide spraying intervention
Number of subjects: 302

Group type: COMPARATOR
Intervention: Mass antibiotic treatment (azithromycin)
Number of subjects: 302